• Analyzing Nanoviricides' Shift to RSV Treatments with Proactive Healthcare Analyst Dr. John Savin

  • May 21 2024
  • Length: 4 mins
  • Podcast
Analyzing Nanoviricides' Shift to RSV Treatments with Proactive Healthcare Analyst Dr. John Savin By cover art

Analyzing Nanoviricides' Shift to RSV Treatments with Proactive Healthcare Analyst Dr. John Savin

Listen for free

View show details

  • Summary

  • Proactive Healthcare Analyst Dr John Savin joined Steve Darling to delved into the recent strategic developments at NanoViricides, shedding light on the company's transition from COVID-19 to respiratory syncytial virus (RSV) treatments. Initially known for its polymer antiviral agent targeting COVID-19, NanoViricides garnered attention with clinical trials conducted in India during the height of the pandemic. However, with the decline of COVID-19 cases, the company has shifted its focus towards tackling RSV, a prevalent lung infection. Dr. Savin highlighted the significance of this pivot, considering RSV's substantial market potential and the limited availability of acute therapies. RSV, currently addressed primarily through vaccines and antibody products, presents a lucrative market valued at $3 billion annually, with forecasts suggesting a potential surge to $8 billion within the next decade. Unlike vaccines requiring pre-infection administration, acute therapies for RSV are scarce, creating a ripe opportunity for Nanoviricides to make a meaningful impact. Dr. Savin outlined NanoViricides' pathway in the RSV space, which entails seeking regulatory approval in the United States. Key milestones in this journey include engaging in discussions with the FDA and submitting regulatory dossiers, a process expected to extend into the spring of the following year. Despite facing financial constraints, with only $3.2 million available, Nanoviricides remains undeterred in its pursuit. The company plans to leverage existing loan facilities, explore market opportunities, and even consider mortgaging assets if necessary to fund its anticipated clinical trials. Dr. Savin estimated the trial cost to be at least $5 million USD, earmarked for the 2026 financial year. Encouraging preclinical data bolster NanoViricides' confidence in the potential success of its upcoming trials. Dr. Savin underscored the importance of focusing on a single indication to accumulate substantial clinical data and establish credibility within the medical community and among investors. Overall, NanoViricides' strategic shift towards RSV treatments signals a calculated move to capitalize on a burgeoning market opportunity, leveraging its expertise and resources to address an unmet medical need and potentially revolutionize the landscape of acute viral infection therapeutics. #proactiveinvestors #nanoviricidesinc #nyseamerican #nnvc #biotec #ClinicalTrials #FDAApproval #NanoVariousSides #COVID19 #VirusTreatment #PolymerAntiviral #USRegulatory #VaccineMarket #Biotechnology #HealthcareFunding #MedicalResearch #PreclinicalData #InfectionTreatment #BiotechFunding #USHealthcare #AntiviralResearch #HealthInnovation #RSVTreatment #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
    Show more Show less
Business & Careers Economics Personal Finance Politics & Government
Show more Show less

What listeners say about Analyzing Nanoviricides' Shift to RSV Treatments with Proactive Healthcare Analyst Dr. John Savin

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available